- Home
- NRO vs MDWD Comparison
NRO vs MDWD Comparison
Compare NRO & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- MDWD
- Stock Information
- Founded
- NRO 2003
- MDWD 2000
- Country
- NRO United States
- MDWD Israel
- Employees
- NRO N/A
- MDWD N/A
- Industry
- NRO Finance/Investors Services
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- NRO Finance
- MDWD Health Care
- Exchange
- NRO Nasdaq
- MDWD Nasdaq
- Market Cap
- NRO 187.8M
- MDWD 184.8M
- IPO Year
- NRO N/A
- MDWD 2014
- Fundamental
- Price
- NRO $3.50
- MDWD $19.02
- Analyst Decision
- NRO
- MDWD Strong Buy
- Analyst Count
- NRO 0
- MDWD 1
- Target Price
- NRO N/A
- MDWD $25.00
- AVG Volume (30 Days)
- NRO 239.4K
- MDWD 61.7K
- Earning Date
- NRO 01-01-0001
- MDWD 11-26-2024
- Dividend Yield
- NRO 11.41%
- MDWD N/A
- EPS Growth
- NRO N/A
- MDWD N/A
- EPS
- NRO N/A
- MDWD N/A
- Revenue
- NRO N/A
- MDWD $19,720,000.00
- Revenue This Year
- NRO N/A
- MDWD $10.37
- Revenue Next Year
- NRO N/A
- MDWD $26.36
- P/E Ratio
- NRO N/A
- MDWD N/A
- Revenue Growth
- NRO N/A
- MDWD N/A
- 52 Week Low
- NRO $2.51
- MDWD $11.04
- 52 Week High
- NRO $3.45
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- NRO 42.49
- MDWD 61.79
- Support Level
- NRO $3.52
- MDWD $15.80
- Resistance Level
- NRO $3.62
- MDWD $18.25
- Average True Range (ATR)
- NRO 0.08
- MDWD 0.88
- MACD
- NRO 0.01
- MDWD 0.07
- Stochastic Oscillator
- NRO 40.00
- MDWD 95.27
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. The fund invests in sectors, such as apartments, Data Centers, Infrastructure REITs, Manufactured Homes, Office, Regional Malls and others.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.